Carlsmed, Inc. (NASDAQ:CARL) Stock Has Consensus Target Price of $19.25 According to Analysts

Shares of Carlsmed, Inc. (NASDAQ:CARL) have been given a consensus rating of “Moderate Buy” by the six analysts that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and four have given a buy recommendation to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $19.50.

A number of brokerages recently weighed in on CARL. BTIG Research lifted their target price on shares of Carlsmed from $23.00 to $24.00 and gave the stock a “buy” rating in a research note on Monday, October 12th. Needham & Company LLC began coverage on shares of Carlsmed in a report on Wednesday, July 1st. They issued a “buy” rating and a $17.00 target price on the stock. Truist Financial upped their price target on shares of Carlsmed from $18.00 to $20.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. Wall Street Zen upgraded Carlsmed from a “sell” rating to a “hold” rating in a report on Saturday, August 15th. Finally, Weiss Ratings raised Carlsmed from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, August 11th.

Institutional Investors Weigh In On Carlsmed

A number of hedge funds have recently added to or reduced their stakes in CARL. Zevenbergen Capital Investments LLC raised its holdings in shares of Carlsmed by 50.4% during the third quarter. Zevenbergen Capital Investments LLC now owns 17,900 shares of the company’s stock valued at $252,000 after purchasing an additional 6,000 shares during the period. Bank of America Corp DE bought a new position in shares of Carlsmed during the 2nd quarter worth about $108,000. Jupiter Topco LLC acquired a new stake in shares of Carlsmed in the 2nd quarter valued at about $12,992,000. Parkman Healthcare Partners LLC acquired a new stake in shares of Carlsmed in the 2nd quarter valued at about $6,200,000. Finally, Alpine Woods Capital Investors LLC acquired a new stake in shares of Carlsmed in the 2nd quarter valued at about $161,000.

Carlsmed Trading Down 3.9%

NASDAQ:CARL traded down $0.54 on Friday, reaching $13.41. 73,221 shares of the stock traded hands, compared to its average volume of 80,104. The company has a current ratio of 8.84, a quick ratio of 8.66 and a debt-to-equity ratio of 0.18. Carlsmed has a 1-year low of $8.50 and a 1-year high of $17.23. The company’s 50 day moving average is $14.99 and its 200-day moving average is $12.38. The firm has a market capitalization of $366.09 million, a price-to-earnings ratio of -9.38 and a beta of 2.09.

Carlsmed (NASDAQ:CARL) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.01. Carlsmed had a negative net margin of 57.42% and a negative return on equity of 38.06%. The firm had revenue of $18.94 million for the quarter. Equities research analysts anticipate that Carlsmed will post -1.50 EPS for the current fiscal year.

About Carlsmed

Carlsmed, Inc is a medical technology company focused on personalized solutions for spine surgery. The company develops patient-specific implants and digital planning tools intended to help surgeons address spinal deformity and degenerative conditions with procedures tailored to an individual patient’s anatomy and surgical goals.

Its principal products are offered under the aprevo brand and include personalized interbody fusion implants produced using three-dimensional printing, along with software that supports implant design and preoperative planning.